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BLIMP1, amaster regulator of plasma-cell differentiation, is implicated in the pathogenesis of ActivatedB cell
(ABC)-like Diffuse Large B cell Lymphoma (DLBCL). In this issue ofCancer Cell,Mandelbaum and colleagues
and Calado and colleagues unequivocally demonstrate that BLIMP1 functions as a tumor suppressor and
guardian of ABC-like DLBCL lymphomagenesis.Diffuse large B cell lymphoma (DLBCL),
the most common subtype of non-Hodg-
kin’s lymphoma (NHL), is a genetically and
clinically heterogeneous disease. The
standard treatment R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincris-
tine, prednisone) cures about 50%–60%
of patients, while the remaining DLBCL
patients succumb to their disease. Better
understanding of DLBCL pathogenesis is
needed in order to identify new thera-
peutic approaches that, hopefully, will
improve outcome and survival of these
patients.
The pathogenesis of DLBCL represents
a complex multistep process involving
collaboration between biological pro-
grams of normal B cells that are utilized
by transformed malignant cells and
multiple acquired genetic and molecular
lesions (Lenz and Staudt, 2010; Lossos,
2005). Therefore, transcriptional pro-
grams characteristic to the specific onto-
genic stages of B cell differentiation from
which the tumors originate, chromosomal
translocations, somatic mutations, as well
as gene amplifications and deletions all
contribute to the complex process of the
molecular pathogenesis of DLBCL.
Marked advances in understanding the
pathobiology of DLBCL have been made
by applying gene expression arrays,
leading to identification of previously
unrecognized germinal center B cell-like
(GCB) and activated B cell-like (ABC)
DLBCL subtypes characterized by
different outcomes (Alizadeh et al.,
2000). This classification of the DLBCL
tumors has also led to the appreciation
that while some genetic and molecular
lesions with known or predicted onco-genic potential occur in both GCB-like
and ABC-like DLBCL subtypes, many
oncogenic pathways are exclusively or
predominantly used by only one subtype
(Table 1). In recent years, there was
marked progress in identifying genetic
and molecular aberrations occurring in
these tumors. However, the roles of
some of the identified aberrations, target-
ing specific genes or signaling pathways,
in the pathogenesis of DLBCL are still
unknown. Moreover, identified pathobio-
logic events do not account for all the
mechanisms underlying the pathogenesis
of these tumors.
The B cell differentiation process
leading to the generation of GC lympho-
cytes and their subsequent differentiation
to memory and plasma cells is tightly
regulated. PR domain-containing 1, with
Zinc Finger Domain 1 (PRDM1), also
known as B-lymphocyte-inducedmatura-
tion protein-1 (BLIMP1), is a master regu-
lator of plasma-cell differentiation.
BLIMP1 is a zinc finger transcriptional
repressor that binds directly to DNA and
acts as a scaffold to recruit multiple core-
pressor proteins, including the histone H3
methyltransferase G9a, the histone de-
acetylase HDAC2, the arginine methyl-
transferase PRMT5, and the histone de-
methylase LSD1 (Bikoff et al., 2009),
thus turning off the gene expression
program of GC andmature B cells. Condi-
tional knockout of Blimp1 in the mouse
B cell compartment leads to an accumu-
lation of activated B cells and a loss of
plasma cell differentiation (Shapiro-Shelef
and Calame, 2005). Conversely, enforced
expression of BLIMP1 in lymphoma cell
lines promotes either partial differentia-Cancer Cell 18, Dtion or apoptosis induction (Messika
et al., 1998). BLIMP1 is highly expressed
at the RNA level in the ABC-like DLBCL
(Alizadeh et al., 2000); however, most of
these tumors lack BLIMP-1 protein
expression. Inactivating mutations of
BLIMP1 have been found in 24% of the
ABC-like DLBCL, but these do not
account for absence of BLIMP1 protein
expression in 77% of these tumors (Pas-
qualucci et al., 2006). Furthermore, while
BLIMP1 inactivation in the ABC-like
DLBCL suggests that it may function as
a tumor suppressor gene, the precise
mechanism by which BLIMP1 aberrations
contribute to lymphomagenesis is
unknown.
In this issue of Cancer Cell, Mandel-
baum et al. (2010) and Calado et al.(2010)
independently and unequivocally demon-
strate that BLIMP1 functions as a tumor
suppressor gene in the pathogenesis of
the ABC-like DLBCL. Furthermore, they
establish the spectrum of the BLIMP1
lesions, show the mechanism by which
mutations affect the BLIMP1 function,
and illustrate collaboration between
BLIMP1 and NF-kB pathway, another
signaling pathway frequently activated in
the ABC-like DLBCL.
Mandelbaum et al. (2010) demonstrate
the presence of BLIMP1 mutations,
including frame-shift insertions and
deletions, splice site mutations, and
nonsense mutations in 27% of ABC-like
DLBCL, but none of the GCB-like tumors,
again confirming the subtype specificity
of the BLIMP1 mutations. Furthermore,
in the majority of these mutated cases,
the authors show the presence of biallelic
inactivation of the gene by wild-typeecember 14, 2010 ª2010 Elsevier Inc. 537
Table 1. Pathogenesis Mechanisms of DLBCL
GCB-like ABC-like
Transcriptional program GC B cells activated B cells
Ongoing Ig somatic mutations ++ –
AID Expression ++ ++
Aberrant Ig class switch recombination/translocation – ++
Aberrant somatic mutations
BCL6 ++ ++
EZH2 ++ –
CD79B – ++
PAX5 – ++
MYC – ++
RhoH/TTF – ++
PIM1 – ++
CARD11 + ++
TNFAIP3(A20) + ++
TNFRSF11A(RANK) + ++
TRAF5 ++ ++
TRAF ++ +
MAP3K7(TAK1) – ++
Constitutive activation of NF-kB – ++
Constitutive activation of STAT3 – ++
Aberrant IL-4 signaling – ++
BCL2 translocations-t(14;18) ++ –
BCL6 translocations ++ ++
MYC translocations ++ ++
Chromosomal alterations gain of 12q12(MDM2) trisomy 3
loss 10q (PTEN) gain/amplification 3q(BCL6, FOXP1)
amplification 2p(REL) gain/amplification18q(BCL2)
loss 13q(ING1) loss 6q21-q22
amplification mir17-92
loss 9p(INK4a/ARF)
gain/amplification 19q(SPIB)
Mutations of TP53 ++ ++
BLIMP1 mutations/deletions – ++
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uniparental disomy of the mutated gene.
They also demonstrate the presence of
biallelic gene deletion and BLIMP1
missense mutations, each in 6% of the
ABC-like DLBCL. The BLIMP1 missense
mutations affect protein stability and/or
its transrepression activity, as demon-
strated experimentally in both 293T and
B cells. In addition, 26% of the ABC-like
DLBCL tumors harbor translocations of
BCL6 and had significantly lower BLIMP1
mRNA levels, implicating known tran-
scriptional repression of BLIMP1 by
BCL6 protein (Tunyaplin et al., 2004).
Indeed, knockdown of BCL6 expression
in DLBCL cell lines harboring BCL6 trans-538 Cancer Cell 18, December 14, 2010 ª20locations promoted increases in BLIMP1
mRNA and protein expression, support-
ing the findings that high BCL6 expression
in ABC-like tumors containing BCL6
translocations may account for low or
absent expression of BLIMP1. Overall,
these findings are of paramount impor-
tance for elucidating the mechanisms
underlying the lack of BLIMP1 protein
expression in the ABC-like DLBCL
tumors. To assess the role of BLIMP1
inactivation in pathogenesis of the ABC-
like DLBCL in vivo, Mandelbaum et al.
generated two types of mice lacking
Blimp1 specifically in B cells. In both
mouse models, there was increased inci-
dence of lymphoproliferative disease10 Elsevier Inc.and DLBCL. The majority of the DLBCL
tumors were IRF4+, negative for GC differ-
entiation markers, and demonstrated
constitutive activation NF-kB, consistent
with the ABC-like phenotype.
Calado et al. (2010) recapitulated in
mice, using a sophisticated genetic
approach, constitutive activation of
NF-kB and Blimp1 inactivation, frequently
found in human ABC-like DLBCL tumors.
Mice with constitutive activation of
NF-kB alone showed similar life spans
as control mice, while deletion of Blimp1
in GC B cells led to shortened survival of
the animals that was further shortened
by concomitant constitutive activation of
the canonical NF-kB pathways. Mice
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pathway demonstrated B cell and plasma
cell hyperplasia, with frequent presence
of serum monoclonal M-spikes. Mice
with Blimp1 inactivation demonstrated
presence of CD138, IRF4+, and BCL6
monoclonal large B cell tumors with highly
somatically mutated immunoglobulin
genes, consistent with an ABC-like
human DLBCL. Similarly, mice with
combined constitutive activation of NF-
kB and BLIMP1 inactivation who showed
shorter survival also developed B cell
lymphomas similar to human ABC-like
DLBCL.
These two manuscripts explicitly
demonstrate that BLIMP1 is a bona-fide
tumor suppressor gene involved in the
pathogenesis of ABC-like DLBCL. They
also prove that blocking differentiation is
an important step in the pathogenesis of
the ABC-like subtype. However, they still
do not resolve the enigma of the nature
of the precursor cell in this subtype.
Furthermore, the study by Calado et al.also clearly demonstrates the synergy in
oncogenesis between lesions that block
differentiation (BLIMP1) and promote
proliferation/survival (NF-kB). However,
the low DLBCL penetrance and long
latency in these mice suggest that addi-
tional transformation events are most
probably required for development of the
ABC-like tumors. A search in mice tumors
for mutations affecting proteins control-
ling activation of the NF-kB (e.g., A20),
commonly found in human ABC-like
DLBCL, was negative. Identifying addi-
tional pathophysiologic mechanisms
contributing to the pathogenesis of
DLBCL and generation of drugs specifi-
cally targeting the ‘‘culprits’’ will be next
important steps.REFERENCES
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In this issue ofCancer Cell, Rui et al. identify JAK2 and JMJDC2 as two contiguous, coamplified oncogenes in
primary mediastinal B cell and Hodgkin lymphoma. Together, JAK2 and JMJD2C induce major changes in
chromatin structure and gene expression. Targeting these proteins with small molecules represents a new
avenue for therapy.The classification of lymphoma hasmoved
beyond morphology to ever more refined
molecular subtypes, with distinct thera-
peutic implications. Gene expression
profiling led to the classification of diffuse
large B cell lymphoma (DLBCL) into acti-
vated B cell, germinal center B cell, and
primary mediastinal B cell lymphoma
(PMBL) subtypes (Dave et al., 2006).Profiling also showed that PMBL and
Hodgkin’s lymphoma (HL) could be
grouped together (Rosenwald et al.,
2003). Genome-wide copy number anal-
ysis coupled with expression profiling rein-
forced the view that these subtypes are
pathogenetically distinct diseases (Lenz
et al., 2008). PMBL and HL, in particular,
frequently display amplification of chromo-somes 2p and 9p. Amplification of REL at
2p14-16, which encodes c-Rel (a subunit
of NF-kB), induces the constitutive activa-
tion of that antiapoptotic pathway.
JAK2 and JMJDC2 were among the
genes previously suspected but not
proved to have pathogenic roles within
the 9p23-24 amplicon. To define the
critical genes within the 9p amplicon inecember 14, 2010 ª2010 Elsevier Inc. 539
